Targeting the hypoxia-inducible factor 2α in placental dysfunction : towards new treatments for preeclampsia and fetal growth restriction

Abstract

Preeclampsia and fetal growth restriction, two main pregnancy complications, are closely linked to placental dysfunction stemming from inadequate uterine artery remodeling. This leads to persistent pulsatile uterine blood flow and the stabilization of HIF-2α, which hinders trophoblast differentiation and elevates sFLT-1 secretion, thus affecting fetal growth and causing maternal symptoms. This work explores the role of hypoxia in placental dysfunction and the potential of PT2385, a specific HIF-2α inhibitor, to mitigate its consequences. Our findings emphasize HIF-2α stabilization in placental stress and the promise of PT2385 in treating severe preeclampsia. This research offers new insights and therapeutic avenues for this critical but incurable condition.(BIFA - Sciences biomédicales et pharmaceutiques) -- UCL, 202